Abstract
Objective To investigate the efficacy and safety of the combination use of tegafur and apatinib as a first-line therapy strategy in advanced gastric cancer (GC). Methods The present study included a total of 62 advanced GC patients. The patients were randomized into the combined group (treated with both tegafur and apatinib) and the control group (treated with only tegafur). Treatment efficacy, KPS score, nutrition condition, and progression-free survival time (PFS) were recorded. Results Both the response and disease control rates were significantly higher in the combined group. The PFS time was remarkably higher and the KPS score was significantly reduced in the combined group after treatment. After treatment, both groups showed significantly increased nutrition risk, but the rates of patients with nutrition risk or innutrition were remarkably higher in the combined group. The ADR rates were also significantly higher in the combined group. Conclusion The combination use could achieve good efficacy and prolong patients' PFS time; however, apatinib also reduced the patients' quality of life and enhanced the nutrition risk and adverse drug reactions.
Highlights
Gastric cancer (GC) is one of the most common cancers worldwide, with a high incidence of 640,000 cases for men and 350,000 cases for women in 2011 [1]
The present study included a total of 69 patients with advanced gastric cancer who went to our hospital during January 2016 to August 2017
All patients were randomized into the combined group (n = 35) and the control group (n = 34)
Summary
Gastric cancer (GC) is one of the most common cancers worldwide, with a high incidence of 640,000 cases for men and 350,000 cases for women in 2011 [1]. Since the early symptoms of GC are always slight and obscure, most GC patients develop to advanced stage upon diagnosis and have lost the best time for radical surgery [2, 3]. Chemotherapy is the key component in the treatment for advanced gastric patients [5]. Patients have to suffer numerous adverse effects and great pain by conventional chemotherapeutic agents [6, 7]. Many new treatment methods are developed, such as checkpoint inhibition and target therapy, which are gradually applied in gastric cancer treatment [8,9,10]. Several drugs for the inhibition of tumor angiogenesis are developed, such as bevacizumab, sunitinib, sorafenib, and ramucirumab [11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
